SEC Form 4 · accession 0001638643-26-000031
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Patrick O'Day
Officer — Chairman & CEO · Director
Period of report
Sep 1, 2026
Accepted (ET)
Sep 2, 2026 · 4:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2026 | S | 1,600 | $147.5087 | D | 590,533 | D | |
| Common StockF3 | Sep 1, 2026 | S | 7,992 | $148.3636 | D | 582,541 | D | |
| Common StockF4 | Sep 1, 2026 | S | 5,408 | $149.3817 | D | 577,133 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- F2Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.